Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
World J Gastroenterol
; 22(18): 4459-65, 2016 May 14.
Article
em En
| MEDLINE
| ID: mdl-27182157
ABSTRACT
Combined hepatocellular cholangiocarcinoma (CHC) accounts for 0.4%-14.2% of primary liver cancer cases and possesses pathological features of both hepatocellular carcinoma and cholangiocarcinoma. Since this disease was first described and classified in 1949, the classification of CHC has continuously evolved. The latest definition and classification of CHC by the World Health Organization is based on the speculation that CHC arises from hepatic progenitor cells. However, there is no evidence demonstrating the common origin of different components of CHC. Furthermore, the definition of CHC subtypes is still ambiguous and the identification of CHC subtype when a single tumor contains many components has remained unresolved. In addition, there is no summary on the newly recognized histopathology features or the contribution of CHC components to prognosis and outcome of this disease. Here we provide a review of the current literature to address these questions.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias dos Ductos Biliares
/
Ductos Biliares Intra-Hepáticos
/
Neoplasias Complexas Mistas
/
Colangiocarcinoma
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article